Perrigo (PRGO) Free Cash Flow (2013 - 2026)
Perrigo's (PRGO) quarterly Free Cash Flow came in at -$127.4 million in Q1 2026, down 41.56% year-on-year from -$218.0 million in Q1 2025, and down 185.73% on a QoQ basis from $148.6 million in Q4 2025.
Perrigo (PRGO) Free Cash Flow (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Free Cash Flow data on file, last reported at -$127.4 million in Q1 2026.
- On a quarterly basis, Free Cash Flow fell 41.56% year-over-year to -$127.4 million in Q1 2026; TTM through Mar 2026 was $107.7 million, a 40.53% decrease from a year earlier, with the FY2025 full-year figure at $145.1 million, down 40.68% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$127.4 million, down from $148.6 million in the prior quarter.
- Over the last five years, Free Cash Flow for PRGO reached as high as $274.9 million in Q4 2024 and fell as low as -$127.4 million in Q1 2026.
- Historically, Free Cash Flow has averaged $45.7 million across 5 years, with a median of $32.9 million in 2023.
- Across the five-year window, Free Cash Flow sank 597.37% in 2024 and soared 400.0% in 2025, its largest moves.
- Year by year, Free Cash Flow stood at $99.8 million in 2022, then soared by 82.36% to $182.0 million in 2023, then surged by 51.04% to $274.9 million in 2024, then slumped by 45.94% to $148.6 million in 2025, then slumped by 185.73% to -$127.4 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$127.4 million in Q1 2026, $148.6 million in Q4 2025, and $29.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | -127.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -127.40 Mn |
| Mar 28, 2026 | -127.40 Mn |
| Dec 31, 2025 | 148.60 Mn |
| Dec 31, 2025 | 148.60 Mn |
| Sep 27, 2025 | 29.80 Mn |
| Sep 27, 2025 | 29.80 Mn |
| Jun 28, 2025 | 56.70 Mn |
| Jun 28, 2025 | 56.70 Mn |
| Mar 29, 2025 | -90.00 Mn |
| Mar 29, 2025 | -90.00 Mn |
| Dec 31, 2024 | 274.90 Mn |
| Dec 31, 2024 | 274.90 Mn |
| Sep 28, 2024 | 15.10 Mn |
| Sep 28, 2024 | 15.10 Mn |
| Jun 29, 2024 | -18.90 Mn |
| Jun 29, 2024 | -18.90 Mn |
| Mar 30, 2024 | -26.50 Mn |
| Mar 30, 2024 | -26.50 Mn |
| Dec 31, 2023 | 182.00 Mn |
| Dec 31, 2023 | 182.00 Mn |